Treatment with an anti-BTLA agonistic antibody decreased IL-2 and IFN-γ production by cytotoxic lymphocytes from CLL patients, whereas BTLA blockade restored cytokine production. The gene discussed is BTLA; the disease is B-cell chronic lymphocytic leukemia.